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The mitotic spindle assembly checkpoint (SAC) ensures faithful chromosome segregation during
mitosis by censoring kinetochore–microtubule interactions. It is frequently rendered dysfunctional
during carcinogenesis causing chromosome missegregation and genomic instability. There are con-
ﬂicting reports whether the HPV16 E7 oncoprotein drives chromosomal instability by abolishing the
SAC. Here we report that degradation of mitotic cyclins is impaired in cells with HPV16 E7 expression.
RNAi-mediated depletion of Mad2 or BubR1 indicated the involvement of the SAC, suggesting that
HPV16 E7 expression causes sustained SAC engagement. Mutational analyses revealed that HPV16 E7
sequences that are necessary for retinoblastoma tumor suppressor protein binding as well as sequences
previously implicated in binding the nuclear and mitotic apparatus (NuMA) protein and in delocalizing
dynein from the mitotic spindle contribute to SAC engagement. Importantly, however, HPV16 E7 does
not markedly compromise the SAC response to microtubule poisons.
& 2012 Elsevier Inc. All rights reserved.Introduction
During mitosis, the cell has to equally segregate replicated
chromosomes into two daughter cells. Kinetochores, complex
protein assemblies on the centromeres of chromosomes, allow
for chromosomes to be captured by microtubules emanating from
the two spindle poles, which is necessary for chromosome
segregation. Capturing of kinetochores by microtubules is by
‘‘trial-and-error’’ and is monitored by the mitotic spindle assem-
bly checkpoint (SAC). The SAC guards genomic integrity by
delaying mitotic chromosome segregation until all chromosomes
are properly attached by spindle microtubules. Chromosome
segregation and mitotic exit require that the mitotic regulators
securin and cyclin B be ubiquitinated by the E3 ubiquitin ligase
anaphase promoting complex/cyclosome (APC/C) before being
targeted for degradation by the proteasome. The SAC thus comes
into play in prometaphase by sequestering the APC/C coactivator
CDC20 and preventing it from activating APC/C (reviewed in
Musacchio and Salmon, 2007).
Studies with anti-microtubule drugs in yeast identiﬁed genes
necessary for the SAC as early as two decades ago. These genes
were named mitotic arrest deﬁcient (MAD) and budding uninhibited
by benzimidazole (BUB) (Hoyt et al., 1991; Li and Murray, 1991).ll rights reserved.
61, Boston, MA 02215, USA.
K. Munger).Evolutionarily conserved from yeast to human, the key cytosolic
SAC effectors Mad2 (MAD2L1), BubR1 (BUB1B) and BUB3 form a
complex with CDC20, known as the mitotic checkpoint complex
(MCC). Depletion of checkpoint proteins including Mad2, BubR1,
and BUB3 have been shown to abolish the SAC (Meraldi et al.,
2004). SAC dysfunction has been linked to development of
aneuploidy during tumorigenesis by studies with human cancer
cell lines with SAC gene mutations and mouse models of SAC
deﬁciency. Moreover, several tumor suppressors and oncogenes
regulate expression and/or activity of SAC proteins (reviewed in
Suijkerbuijk and Kops, 2008).
Human papillomaviruses (HPVs) are small DNA viruses that
infect squamous epithelia of the skin or mucous membranes.
HPVs infect the proliferating basal cell layer through microabra-
sions or at squamocolumnar transformation zones where basal-
like cells are exposed. HPV genomes are maintained as episomes
and the productive phase of the viral life cycle occurs exclusively
in differentiated cells. Since HPVs are acutely dependent on
cellular replication factors, HPVs need to uncouple the prolifera-
tion/differentiation switch, an activity that is mainly executed by
the E7 protein. Malignant progression of high-risk HPV-associated
lesions is a relatively rare event, and is accompanied by accumu-
lation of structural and numerical chromosome aberrations. The
high-risk HPV E6 and E7 proteins, which are consistently
expressed in HPV-associated lesions and cancers, have been
shown to induce genomic instability through a number of
different mechanisms (reviewed in Klingelhutz and Roman,
2012; McLaughlin-Drubin and Munger, 2009).
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targeting the retinoblastoma tumor suppressor (pRB) for protea-
somal degradation (Huh et al., 2007), but also drives genomic
destabilization. HPV16 E7 expression causes synthesis of super-
numerary centrosomes, chromosome alignment delays, and per-
sistent presence of double strand DNA breaks (Duensing et al.,
2001; Duensing and Munger, 2002; Nguyen and Munger, 2009),
each of which is likely to impair the ﬁdelity of mitosis and trigger
SAC activation. Several studies have suggested that HPV16 E7
expression abrogates the SAC, with cells escaping prolonged
mitotic arrest and developing polyploidy in the presence of
microtubule poisons (Patel et al., 2004; Thomas and Laimins,
1998). There is also the opposite view that instead of abrogating
the SAC, HPV16 E7 abolishes a postmitotic checkpoint, which
becomes active and prevents further cell cycle progression when
cells adapt to the SAC, decondense their chromosomes and
undergo mitotic slippage to a G1-like state with 4N DNA
(Heilman et al., 2009; Khan and Wahl, 1998).
Previous live-cell imaging studies in our lab revealed a
prometaphase delay in cells with HPV16 E7 expression (Nguyen
and Munger, 2009), suggestive of SAC activation. Here we report
that the expression of HPV16 E7 impedes the degradation of
mitotic cyclins and that this is in part dependent on E7 mediated
SAC engagement. We also demonstrate the functionality of the
SAC in response to microtubule poisons in cells with HPV16 E7
expression. We hypothesize that a functional SAC may contribute
to the viral life cycle by ensuring viral genome persistence.Results
HPV16 E7 expression impedes cyclin B degradation during mitosis.
Previous immunoﬂuorescence and live-cell imaging studies in
our lab demonstrated a prometaphase delay associated with
HPV16 E7 expression (Nguyen and Munger, 2009). Despite earlier
reports that linked the expression of HPV16 E7 alone or together
with HPV16 E6 to the abrogation of the SAC (Patel et al., 2004;Fig. 1. HPV16 E7 expression impedes cyclin B degradation during mitosis in RKO cells
were collected at different times after release from a double thymidine block. Shown he
experiments. (A) Western blot analyses of pRB, E7, histone H3 phosphorylated at serin
relative to actin are indicated above the cyclin B blot. Values are presented relative to th
the relative cyclin B levels normalized to actin, providing a basis for comparison of RKO
RKO E7 at different times after release from a double thymidine block.Thomas and Laimins, 1998), we did not observe frequent conver-
sion of delayed chromosome congression in E7-expressing cells
during metaphase into lagging chromosomes in anaphase
(Nguyen and Munger, 2009). This led us to hypothesize that the
SAC is still functional in HPV16 E7-expressing cells. To address
this, we examined the degradation of cyclin B in mitosis, which is
directly inhibited by the SAC (Musacchio and Salmon, 2007), in
HPV16 E7-expressing cells.
Colon carcinoma RKO cells were initially used for these
experiments because they have wild type p53 and pRB tumor
suppressor activity and an intact SAC (Cahill et al., 1998). More-
over, clonal RKO lines with high-level HPV16 E7 expression have
been described (Slebos et al., 1994) (Fig. 1A). To compare cell
cycle progression of HPV16 E7-expressing RKO cells (RKO E7) to
control vector transfected cells (RKO C), cells were subjected to a
double thymidine block, which causes a G1/S arrest. We per-
formed cell cycle analyses by FACS after propidium iodide stain-
ing and quantiﬁed the percentage of G2/M cells (4N DNA). RKO C
and RKO E7 cells responded equally well to double thymidine
synchronization, with only 10% of cells in G2/M at the time of
release from double thymidine block (Fig. 1B). After release from
the double thymidine block we investigated the mitotic markers
phospho histone H3 serine 10 (pH3S10) and cyclin B for a time
period of 14 h, during which most RKO C and RKO E7 cells
synchronously progressed through G2 and M phase (Fig. 1B).
Cyclin B levels peaked at 8 h and 10 h post release in RKO C and
RKO E7 cells, respectively, consistent with the high levels of
pH3S10 at these time points. By 14 h post release, cyclin B levels
decreased by 56% from its peak levels in RKO C cells, while only
an 18% decrease was observed in RKO E7 cells, suggesting that
cyclin B degradation during mitosis may be inhibited in RKO E7
cells (Fig. 1A).
We decided to use primary human foreskin ﬁbroblasts (HFFs)
for more detailed analyses of SAC engagement in response to
HPV16 E7 expression. HFFs were used for several reasons: even
though RKO cells retain SAC function (Cahill et al., 1998) they are
a cancer derived line and may contain mutations that affect the
proper functioning of the SAC. In addition, the fact that RKO C and. RKO cells with stable expression of empty vector (RKO C) or HPV16 E7 (RKO E7)
re is a representative experiment; similar results were obtained in two additional
e 10 (pH3S10), histone H3, cyclin B and actin are shown. Cyclin B quantiﬁcations
e highest (1) in either RKO C or RKO E7. The bar graph below the actin blot shows
C and RKO E7. (B) FACS analyses of G2/M cell populations are shown for RKO C and
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peaks by FACS (Fig. 1B) and cyclin B peaks by Western blots
(Fig. 1A) complicates our interpretation that cyclin B degradation
is inhibited during mitosis and may simply reﬂect delayed
accumulation of cyclin B prior to the metaphase-to-anaphase
transition in RKO E7 cells. Whereas keratinocytes, not ﬁbroblasts
are the natural host cells of HPVs, HFFs have a higher mitotic
index than keratinocytes, which makes them amenable to mitotic
analyses as well as double thymidine synchronization.
We generated donor and passage matched primary HFF
populations infected with empty vector (HFF C) or HPV16 E7
(HFF E7) (Fig. 2A). The two cell populations were arrested at the
G1/S boundary by double thymidine block and, after release, we
followed their passage through the cell cycle by FACS (Fig. 2B). In
HFF C, cyclin B levels peaked at 8 h after release from double
thymidine block and decreased by 76% by 14 h post release. In
HFF E7, cyclin B levels also peaked at 8 h post release but
decreased by only 59% by 14 h post release (Fig. 2C). Moreover,
cyclin B levels were already markedly higher in double thymidine
block G1/S arrested HFF E7 cells than in HFF C cells (2 fold
difference, Fig. 2C). Hence these experiments demonstrate that
HPV16 E7 expression impedes the mitotic degradation of cyclin B
in primary HFFs.
The pRB-binding domain as well as C-terminal HPV16 E7 sequences
are necessary for the impairment of mitotic cyclin B degradation.
To determine which functions of HPV16 E7 may contribute to
the inhibition of cyclin B degradation, we assessed HFFs expres-
sing wild-type E7, or the HPV16 E7D21-24 and HPV16 E7D79-83
mutants. The pRB family binding deﬁcient HPV16 E7D21-24 and
the p21CIP1 and p27KIP1 binding defective HPV16 E7D79-83
mutants (Funk et al., 1997; Zerfass-Thome et al., 1996) have been
previously characterized for their abilities to induce disorganized
metaphases, which presumably represents a prometaphase delay
(Nguyen and Munger, 2009).
Even though the two E7 mutants did not appear to be expressed
at the same levels as wild-type E7 by Western blot (Fig. 3A), pRB
levels were similarly decreased in wild type HPV16 E7 and HPV16
E7D79-83 mutant expressing HFFs (Fig. 3B) suggesting that the
HPV16 E7D79-83 mutant was expressed at levels that wereFig. 2. HPV16 E7 expression impedes cyclin B degradation during mitosis in primary hu
C) or HPV16 E7 (HFF E7) were collected at different times after release from a double
obtained in two additional experiments. (A) Western blot analysis of E7 expression in th
HFF C and HFF E7 at different times after release from a double thymidine block. (C) We
B quantiﬁcations relative to actin are indicated above the cyclin B blot. Values are prese
actin blot shows the relative cyclin B levels normalized to actin, providing a basis forsufﬁcient for functionality. The HPV16 E7D21-24 mutant is not
recognized by the ED17 antibody (Psyrri et al., 2004), which may
result in decreased detection of this mutant in our Western blots.
HFFs with stable expression of empty vector, wild-type E7, E7D21-
24, and E7D79-83 exhibited similar cell cycle proﬁles after release
from a double thymidine block (Fig. 3C). Consistent with what we
observed before (Fig. 2), HPV16 E7 expression impeded mitotic
cyclin B degradation, with cyclin B levels decreasing by 47% from 8 h
to 14 h post release, compared to an 89% decrease over the same
period of time in HFF C. Similar to HFF C, cyclin B levels decreased by
80% and 90% in HFFs expressing the HPV16 E7D21-24 and HPV16
E7D79-83 mutants, respectively. Therefore, both the pRB-binding
domain and C-terminal HPV16 E7 sequences contribute to inhibition
of mitotic cyclin B degradation.
HPV16 E7 engages SAC-dependent and -independent pathways to
impede the degradation of mitotic cyclins.
In order to address whether engagement of the SAC accounts for
E7 mediated inhibition of cyclin B degradation during mitosis, we
transfected HFF C and HFF E7 with siRNA pools targeting the SAC
effectors Mad2 or BubR1 before synchronizing the cells for cell cycle
analyses. Both Mad2 and BubR1 expression was efﬁciently reduced
after siRNA transfection (Fig. 4). Cyclin B was more efﬁciently
degraded in HFF E7 cells after depletion of Mad2 (45%) or BubR1
(48%) as compared to control siRNA transfected cells (31%) (Fig. 4).
We also assessed steady state levels of cyclin A, an APC/C substrate
not subject to SAC regulation (den Elzen and Pines, 2001; Geley
et al., 2001). In HFF C, cyclin A levels decreased by 70% at 14 h post
release from a double thymidine block, whereas the decrease was
only 29% in HFF E7 cells. Cyclin A levels did not decrease more
efﬁciently in HFF E7 cells upon depletion of Mad2 (0%) or BubR1
(18%) (Fig. 4). Hence, we conclude that HPV16 E7 engages both SAC-
dependent and SAC-independent mechanisms to impede the degra-
dation of mitotic cyclins.
HPV16 E7 expression does not compromise the SAC response to
microtubule poisons.
Our experiments so far revealed that in a synchronized but
otherwise unperturbed cell cycle, cyclin B degradation did notman foreskin ﬁbroblasts (HFFs). HFFs with stable expression of empty vector (HFF
thymidine block. Shown here is a representative experiment; similar results were
e stable HFF populations. (B) FACS analyses of G2/M cell populations are shown for
stern blot analyses of pRB, pH3S10, histone H3, cyclin B and actin are shown. Cyclin
nted relative to the highest (1) in either HFF C or HFF E7. The bar graph below the
comparison of HFF C and HFF E7.
Fig. 3. HPV16 E7D21-24 or HPV16 E7D79-83 mutants are defective for inhibition of cyclin B degradation during mitosis. HFFs with stable expression of empty vector (C),
HPV16 E7 (E7), HPV16 E7D21-24 (D21-24), or HPV16 E7D79-83 (D79-83) were collected at different times after release from a double thymidine block. Shown here is a
representative experiment; similar results were obtained in three additional experiments with different HFF populations. (A) Western blot analysis of E7 expression in the
stable HFF populations. (B) Western blot analyses of pRB, pH3S10, histone H3, cyclin B and actin are shown. Cyclin B quantiﬁcations relative to actin are indicated above
the cyclin B blot. Values are presented relative to the highest (1) in C, HPV16 E7, HPV16 E7D21-24, or HPV16 E7D79-83 expressing cells. (C) FACS analyses of G2/M cell
populations are shown for HFF C, HPV16 E7, HPV16 E7D21-24, and HPV16 E7D79-83 expressing cells at different times after release from a double thymidine block.
Fig. 4. HPV16 E7 impedes the degradation of mitotic cyclins through SAC-
dependent and SAC-independent mechanisms. HFFs with stable expression of
empty vector (C) or HPV16 E7 (E7) were transfected with non-targeting control
siRNAs, siMad2, or siBubR1 before subjected to a double thymidine block. Western
blot analyses of pRB, Mad2, BubR1, pH3S10, histone H3, cyclin B, cyclin A and actin
are shown. Cyclin B and cyclin A quantiﬁcations relative to actin are indicated
above the respective blots. Values are presented relative to the highest (1) in each
condition. Shown here is a representative experiment; similar results were
obtained in three additional experiments.
Fig. 5. HPV16 E7 expression does not compromise the SAC response to microtubule
poisons. (A) HFFs with stable expression of empty vector (HFF C) or HPV16 E7 (HFF E7)
were G1/S arrested by treating with thymidine for 24 h and released into medium
containing DMSO, nocodazole, or taxol at the indicated concentrations for 18 h.
(B) HFKs with stable expression of empty vector (HFK C) or HPV16 E7 were treated
with DMSO, nocodazole, or taxol at the indicated concentrations for 24 h. Mitotic
indices were determined by FACS analyses withMPM-2 and propidium iodide staining.
The bar graph shows averages and standard deviations from three independent
experiments. Statistically signiﬁcant differences (Po0.05) between control and E7
expressing HFKs as determined by Student’s t-test are denoted by an asterisk.
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cells, and this was in part dependent on a functional SAC. We
therefore decided to also examine the SAC response to micro-
tubule poisons, a standard laboratory test for SAC activity. We
arrested HFF C and HFF E7 cells at the G1/S boundary by a single
thymidine block before treatment with nocodazole or taxol for
18 h (Fig. 5A). This time was chosen because cells do not remain
arrested in M phase for extended periods of time but eventually
undergo mitotic slippage to a tetraploid G1-like state (Taylor and
McKeon, 1997). The nocodazole concentrations that we tested
included the 50 ng/ml dose that was used in a previous report
suggesting that HPV16 E7 expression bypassed the SAC (Thomas
and Laimins, 1998) as well as a higher dose of 200 ng/ml that wasused to document mitotic arrest followed by slippage from
mitosis after 18 h (Taylor and McKeon, 1997). We also tested a
range of taxol concentrations that have been shown in previous
Y. Yu, K. Munger / Virology 432 (2012) 120–126124studies to allow for differential detection of various degrees of
SAC defects (Wang et al., 2010).
Only 1.1% of HFF C and 1.5% of HFF E7 were in mitosis in DMSO
treated cells at 18 h post release from the thymidine block
(p¼0.48). HFF C and HFF E7 cells arrested in mitosis with similar
efﬁciencies at all nocodazole concentrations tested, with HFF E7
performing slightly better although these differences were not
signiﬁcant statistically (at 50 ng/ml: 41.8% HFF E7 compared
to 34.4% HFF C, p¼0.13; at 100 ng/ml: 41.3% HFF E7 compared
to 34.3% HFF C, p¼0.1; at 200 ng/ml: 38.3% HFF E7 compared to
32.6% HFF C, p¼0.19). The range of taxol concentrations tested
rendered a dose response of arrest efﬁciency, and at all concentra-
tions HFF E7 showed somewhat higher degrees of mitotic arrest,
although these were not statistically signiﬁcant (at 33 nM: 14.8%
HFF E7 compared to 13.9% HFF C, p¼0.54; at 100 nM: 23.4% HFF E7
compared to 16.2% HFF C, p¼0.14; at 1000 nM: 50.4% HFF E7
compared to 45.6% HFF C, p¼0.39).
Previous experiments reporting subversion of the SAC by
HPV16 E7 expression were performed with primary human fore-
skin keratinocytes (HFKs) (Patel et al., 2004; Thomas and Laimins,
1998). Therefore, we generated donor and passage matched
primary HFK populations infected with empty vector (HFK C) or
HPV16 E7 (HFK E7). Since we could not achieve good thymidine
synchronization with HFKs, we treated the cells with various
concentrations of nocodazole and taxol for 24 h without prior
thymidine treatment (Fig. 5B). As expected, DMSO-treated HFKs
had lower mitotic indices than HFFs. HFK C and HFK E7 cells
arrested with similar efﬁciencies in nocodazole (at 50 ng/ml: 4.3%
HFK E7 compared to 4.5% HFK C, p¼0.9; at 100 ng/ml, 5.9% HFK
E7 compared to 5.6% HFK C, p¼0.57; at 200 ng/ml, 7.2% HFK E7
compared to 6.2% HFK C, p¼0.23). Interestingly, however, HFK E7
showed statistically higher degrees of mitotic arrest in taxol (at
33 nM, 12.1% HFK E7 compared to 9.9% HFK C, p¼0.03; at 100 nM,
12.2% HFK E7 compared to 9.2% HFK C, p¼0.005; at 1000 nM, 9.1%
HFK E7 compared to 6.8% HFK C, p¼0.02).
In conclusion, equally robust or sometimes higher degrees of
mitotic arrest in response to microtubule poisons suggested that
HPV16 E7 expression in primary human ﬁbroblasts or keratino-
cytes does not impair the SAC or drive mitotic slippage in primary
cells in response to nocodazole or taxol treatment.Discussion
Previous studies in our lab hinted at the possibility that the
SAC may remain functional in HPV16 E7-expressing cells. Despite
the increased incidence of disorganized metaphases in HPV16
E7-expressing cells under ﬁxed conditions revealed by immuno-
ﬂuorescence, live-cell imaging experiments suggested that these
disorganized metaphases actually represented a prometaphase
delay and that such cells eventually progressed into normal meta-
and anaphases (Nguyen and Munger, 2009). Here we show that
mitotic cyclin B degradation is impaired by HPV16 E7 expression
in a synchronized but otherwise unperturbed cell cycle
(Figs. 1 and 2). This result suggests that HPV16 E7 expression
may trigger the SAC, which directly inhibits cyclin B degradation.
One caveat of this interpretation is that E7 encoded by another
high-risk HPV, HPV18, has been reported to cause a prolonged G2
phase following S phase reentry in raft cultures of differentiated
human keratinocytes (Banerjee et al., 2011). Hence, we needed to
determine whether the observed sustained cyclin B levels during
mitosis in HPV16 E7 expressing cells may reﬂect a delay in
mitotic entry due to a prolonged G2 phase. Indeed, RKO E7 cells
achieved peak cyclin B levels later than RKO C cells (Fig. 1). This
prompted us to examine primary human ﬁbroblasts with E7
expression. HFF E7 cells progressed through the cell cycle withsimilar kinetics as HFF C cells after synchronization with a double
thymidine block and cyclin B was still not degraded as efﬁciently
in HFF E7 as in HFF C (Fig. 2). We observed higher levels of cyclin
B in cells with HPV16 E7 expression in late S and G2 (0 and 4 h
after release from a double thymidine block, respectively-
Figs. 1 and 2). This is consistent with the model that high-risk
HPV E7 upregulates cyclin B expression (Banerjee et al., 2011)
and/or causes incomplete degradation of mitotic cyclin B. How-
ever, this does not mask the effects of HPV16 E7 on mitotic cyclin
B degradation because cyclin B levels accumulated to similar
peaks during mitosis in control- and E7-expressing cells
(Figs. 1 and 2).
In contrast to wild type HPV16 E7, expression of the pRB
family binding/degradation deﬁcient HPV16 E7D21-24 and the
C-terminal HPV16 E7D79-83 mutants did not impede cyclin B
degradation (Fig. 3). It has been shown that pRB inactivation
results in a hyperactive SAC and delayed mitotic progression, and
that the deregulated expression of Mad2, an E2F target gene, is an
important mediator of this effect (Hernando et al., 2004). Indeed
we observed slightly higher Mad2 levels in cells with HPV16 E7
expression (Fig. 4). Hence, the reduced inhibition of cyclin B
degradation by the HPV16 E7D21-24 mutant may reﬂect that this
mutant cannot interact with and degrade pRB and thus will not
deregulate Mad2 transcription through E2F. The HPV16 E7D79-83
mutant, while competent for pRB degradation (Helt et al., 2002),
is defective for dynein delocalization from mitotic spindles and
cannot interact with NuMA (Nguyen et al., 2008; Nguyen and
Munger, 2009). Dynein is a minus-end directed microtubule
motor protein that has been implicated in the inactivation of
the SAC by ‘‘stripping’’ checkpoint proteins off the kinetochores
via transport along microtubules (reviewed in Musacchio and
Salmon, 2007). NuMA is involved in mitotic spindle organization
and chromosome alignment (Levesque et al., 2003). Accordingly,
HPV16 E7 may thwart cyclin B degradation by causing sustained
SAC activation through E2F mediated, dysregulated Mad2 expres-
sion and by inhibiting dynein-mediated SAC inactivation as well
as NuMA function.
We investigated whether E7 triggered SAC engagement con-
tributes to impaired cyclin B degradation by depleting Mad2 or
BubR1 in HFF E7 cells (Fig. 4). While cyclin B degradation kinetics
in Mad2 or BubR1 depleted HFF E7 cells were not completely
restored to levels seen in HFF C, it is possible that the residual
levels of these checkpoint proteins on the kinetochores, although
not readily detectable by Western blotting of whole cell lysates,
may still support some SAC signaling. The inability of Mad2 or
BubR1 depletion to reverse impaired cyclin A downregulation in
HFF E7 cells, however, underlines the speciﬁcity of our assay and
also points to a SAC-independent aspect of the inhibition of
mitotic cyclin degradation by E7. Future studies will examine
the degradation of other APC/C substrates such as Aurora B and
CDC20 (Peters, 2006) in HPV16 E7-expressing cells. Since E7 has
no intrinsic enzymatic activities and perturbs cellular pathways
mainly through protein–protein interactions, proteomics studies
of E7 in mitotic extracts may provide some clues to the under-
lying mechanism of how E7 impairs the proteasomal degradation
of mitotic cyclins.
We offered direct evidence that the SAC is not impaired by
HPV16 E7 expression in response to the microtubule poisons,
nocodazole and taxol (Fig. 5). The previous studies reporting that
HPV16 E7 expression bypassed the SAC triggered by nocodazole
may arise from SAC adaptation and mitotic slippage during
prolonged drug treatment (Taylor and McKeon, 1997; Thomas
and Laimins, 1998). Evidences abound for viral oncoproteins
targeting the SAC, including the SV40 large T antigen (Cotsiki
et al., 2004), HTLV-1 oncoprotein Tax (Jin et al., 1998), and HBV X
protein (Kim et al., 2008). Although abrogating the SAC can
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HPV16 E7 expressing cells may need to retain a functional SAC.
HPV16 E7 disrupts the organization of a bipolar mitotic spindle
through induction of supernumerary centrosomes and by dis-
rupting NuMA function (Duensing et al., 2001; Nguyen and
Munger, 2009). HPV16 E7 may also obstruct the chromosome
alignment process by associating with NuMA and harboring DNA
double strand breaks (Duensing and Munger, 2002; Nguyen and
Munger, 2009). A functional or even a sustained SAC due to
interference with SAC inactivation by disrupting dynein function
(Nguyen et al., 2008) in E7 expressing cells may provide an
extended window of time to resolve these potentially lethal
genetic abnormalities and achieve faithful chromosome segrega-
tion. The ability to undergo mitosis that yields viable daughter
cells is essential for HPV infected cells to efﬁciently maintain and
segregate viral episomes.
In conclusion, we have shown that cells with HPV16 E7
expression retain a functional SAC both in a synchronized setting
and in response to microtubule poisons. Mitotic errors due to SAC
inactivation can result in the generation of nonviable progeny,
which would also result in the loss of viral genomes and interfere
with persistent infection as well as the viral life cycle. Hence, we
hypothesize that sustained SAC activity due to HPV E6 and E7
induced genomic instability may facilitate viable mitosis that is
essential for viral genome maintenance.Materials and methods
Cells: RKO pC (pCMV control cells) and RKO7.6 (E7-expressing)
cells (Slebos et al., 1994), a generous gift from Kathleen Cho
(University of Michigan, Ann Arbor MI), were maintained in
modiﬁed McCoy’s medium (Gibco Invitrogen) supplemented with
10% newborn calf serum (NCS), 50 U/ml penicillin, 50 mg/ml
streptomycin, and 500 mg/ml G418. Primary human foreskin
ﬁbroblasts (HFFs) and human foreskin keratinocytes (HFKs) were
isolated from anonymous newborn circumcisions as previously
described (McLaughlin-Drubin et al., 2008). HFFs with stable
expression of wild-type or mutant HPV16 E7 were generated by
infecting primary HFF populations with the following pBABE-
puromycin-based retroviral vectors: pBABE, pBABE-16E7, pBABE-
16E7 D21-24 and pBABE-16E7 D79-83. Recombinant retroviruses
were produced in 293 T cells as previously described
(Piboonniyom et al., 2003). Infections of 50% conﬂuent HFFs were
performed with a mixture of 2 ml viral supernatant, 8 mg/ml
Polybrene, and 2 ml Dulbecco’s modiﬁed Eagle medium (DMEM)
for 4–6 h. The cells were maintained in DMEM supplemented
with 10% NCS, 50 U/ml penicillin and 50 mg/ml streptomycin.
HFKs with stable expression of HPV16 E7 were generated by
retroviral infection with pLXSN based vectors and maintained in
keratinocytes serum-free medium (KSFM) supplemented with
human recombinant epidermal growth factor 1–53, bovine pitui-
tary extract (Invitrogen), 50 U/ml penicillin and 50 mg/ml strep-
tomycin, 20 mg/ml gentamicin, and 1 mg/ml amphotericin B. All
experiments were performed with HFF or HFK populations
passaged less than ten times.
Western blotting and antibodies
Cells were lysed in ML buffer (300 mMNaCl, 0.5% Nonidet P-40
[NP-40], 20 mM Tris–HCl [pH 8.0], 1 mM EDTA) supplemented
with one complete EDTA-free protease inhibitor cocktail tablet
(Roche) per 25 ml lysis buffer and one PhosSTOP phosphatase
inhibitor cocktail tablet (Roche) per 10 ml lysis buffer. Lysates
were cleared by centrifugation at 16,000 g for 15 min at 4 1C.
Protein concentrations were determined by Bradford assay (Bio-Rad). Proteins were separated by SDS-PAGE and electro trans-
ferred onto polyvinylidene diﬂuoride membranes (Immobilon-P;
Millipore). Membranes were blocked in 5% nonfat dry milk in
TNET buffer (200 mM Tris–HCl, 1 M NaCl, 50 mM EDTA, 0.1%
Tween 20 [pH 7.5]) or 5% BSA in TBST (137 mM NaCl, 2.7 mMKCl,
25 mM Tris [pH 7.4], 0.1% Tween 20) and probed with appropriate
antibodies. The following primary antibodies were used at the
indicated dilutions: HPV16 E7 (8C9, Zymed/Invitrogen, 1:150
mixed with ED17, Santa Cruz Biotechnology, 1:200); pRB (AB-5,
CalBiochem, 1:100); pH3S10 (ab5176, Abcam, 1:500), histone H3
(9715, Cell Signaling, 1:1,000), cyclin B (610219, BD Transduction
Laboratories, 1:1,000), cyclin A (sc-751, Santa Cruz Biotechnology,
1:500), Mad2 (610679, BD Transduction Laboratories, 1:1,000),
BubR1 (05-898, Upstate/Millipore, 1:1,000), and actin (MAB1501,
Millipore, 1:1,000). Secondary anti-mouse and anti-rabbit anti-
bodies conjugated to horseradish peroxidase were used at a
1:10,000 dilution. Proteins were visualized by enhanced chemi-
luminescence (Perkin Elmer, Millipore) and exposed on Kodak
BioMax XAR ﬁlm, or electronically acquired with a Kodak Image
Station 4000R equipped with Kodak Imaging Software, version
4.0, or with Carestream Gel Logic 4000.
Cell synchronization and RNAi
RKO and HFF cells were synchronized by a double thymidine
block by treating cells with 2 mM thymidine for 18 h, followed by
an 8 h release in normal medium and treatment with 2 mM
thymidine for an additional 16 h. For siRNA transfection,
1.5105 HFF cells were seeded in 6 cm plates one day before
transfection with 200 pmol MAD2L1-speciﬁc ON-TARGETplus
SMARTpool (L-003271-00-0005; Thermo Scientiﬁc Dharmacon)
or BUB1B-speciﬁc ON-TARGETplus SMARTpool (L-004101-00-
0005; Thermo Scientiﬁc Dharmacon), or ON-TARGETplus Non-
Targeting Pool (D-001810-10-05; Thermo Scientiﬁc Dharmacon)
using Lipofectamine 2000 (Invitrogen). One day after siRNA
transfection, HFFs were subjected to a double thymidine block
and harvested for Western blot analyses.
Flow cytometry
For cell cycle analyses by propidium iodide staining, cells were
harvested at different times after release from a double thymidine
block and ﬁxed with 70% ice-cold ethanol. Cells were then
incubated in 30 mg/ml propidium iodide, 100 mg/ml RNAse A, in
phosphate buffered saline (PBS) for 30 min at room temperature
in the dark. To speciﬁcally quantify mitotic cells in response to
drug-induced mitotic arrest, HFFs were treated with 2 mM
thymidine for 24 h followed by nocodazole (Sigma) or taxol
(Sigma) treatment at the indicated concentrations for 18 h. HFKs
were treated with nocodazole or taxol at the indicated concentra-
tions for 24 h. Cells were then ﬁxed with 70% ice-cold ethanol,
rinsed with 1% fetal calf serum (FCS) in PBS, stained for MPM-2
(05-368, Upstate/Millipore, 1:1,000) for one hour at room tem-
perature, and with Alexa Fluors 488 Goat Anti-Mouse IgG (HþL)
(Molecular Probes/Invitrogen, 1:400) for one hour at room tem-
perature in the dark followed by propidium iodide staining as
described above. Flow cytometry was conducted on a FACSCalibur
(Becton Dickinson, Franklin Lakes, NJ). Data were acquired using
the CellQuest software (Becton Dickinson) and analyzed with
CellQuest or FlowJo 7.6.1.Acknowledgments
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